Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Skin Cancer

Skin Cancer

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Skin Cancer

59 trials tracked for Skin Cancer: 2 in phase 3 or 4.

59Trials tracked
2Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 4 1 Phase 3 1 Phase 2 31 Phase 1 5 Other / NA 21
  1. Phase 4 Topical Antibiotic Prophylaxis for Eyelids Completed
  2. Phase 3 An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma Completed
  3. Phase 2 Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors Completed
  4. Phase 2 ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin Completed
  5. Phase 2 Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer Completed
  6. Phase 2 Pomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus Infection Completed
Show 44 more trials
  1. Phase 2 Eflornithine and/or Diclofenac in Treating Patients With Sun-Damaged Skin Completed
  2. Phase 2 Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy Completed
  3. Phase 2 Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma Completed
  4. Phase 2 Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma Completed
  5. Phase 2 Photodynamic Therapy in Treating Patients With Skin Cancer Completed
  6. Phase 2 Study of ADI-PEG 20 in Patients With Advanced Melanoma Completed
  7. Phase 2 A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma Completed
  8. Phase 2 sEphB4-HSA in Treating Patients With Kaposi Sarcoma Completed
  9. Phase 2 Study of TVEC in Patients With Cutaneous Squamous Cell Cancer Completed
  10. Phase 2 Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma Completed
  11. Phase 2 Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI... Completed
  12. Phase 2 Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ Basal Cell Carcinomas Completed
  13. Phase 2 Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia Completed
  14. Phase 2 Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma Completed
  15. Phase 2 Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer Completed
  16. Phase 2 Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer Completed
  17. Phase 2 Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma Completed
  18. Phase 2 Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes Completed
  19. Phase 2 Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M... Completed
  20. Phase 2 Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma Completed
  21. Phase 2 Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma Completed
  22. Phase 2 Preventing Squamous Cell Skin Cancer Completed
  23. Phase 2 Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma Completed
  24. Phase 2 Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma Completed
  25. Phase 2 Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection Completed
  26. Phase 2 Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back Completed
  27. Phase 2 Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer Completed
  28. Phase 1 SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas Completed
  29. Phase 1 Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC) Completed
  30. Phase 1 Evaluation of Adherence to Topical Agents: Applying Communication Technology to Improve Sunscreen Use Completed
  31. Phase 1 Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma Completed
  32. Phase 1 Assessing a Natural Product Plus Bioadhesive Nanoparticle (BNP) Sunscreen Completed
  33. N/A Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer Completed
  34. N/A RECELL® System Combined With Meshed Autograft for Reduction of Donor Skin Harvesting in Soft Tissue Reconstruction Completed
  35. N/A Scar Appearance After Postoperative Hydrocolloid Dressing Versus Standard Petrolatum Ointment Completed
  36. N/A Social Media Indoor Tanning Study Completed
  37. N/A Post Excision/Mohs Scar Laser Resurfacing Completed
  38. N/A Safety and Efficacy of Oral Midazolam for Perioperative Anxiety Relief of Patients Undergoing Mohs Micrographic Surgery Completed
  39. N/A An Appearance-Based Intervention to Reduce Teen Skin Cancer Risk Completed
  40. N/A Strategies to Promote Skin Health Completed
  41. N/A Virtual Sun Safe Workplaces Ph II (SSW Works) Completed
  42. N/A Microwave Therapy for Treatment of Precancerous Actinic Keratoses Completed
  43. N/A Effect of Dermal Rejuvenation on the UVB Response of Geriatric Skin Completed
  44. N/A The Impact of Total Body Skin Examination on Skin Cancer Detection Completed

Showing the 50 most-cited and recently-updated of 59 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Skin Cancer: what the trials found

Pembrolizumab has been evaluated in clinical trials for skin cancer, with data showing that 100% of participants experienced adverse events during the study period 17. Additionally, Pembrolizumab was assessed in a separate trial involving a small cohort 10.

The use of a topical antibiotic product demonstrated a statistically significant reduction in the number of participants with surgical site infections (0 vs 5; p=0.025) compared to a control group. No significant differences were observed regarding wound dehiscence (p=0.77) or allergic contact dermatitis (p=1.00) 4.

BMS-986205 was evaluated in a Phase 3 trial for this condition 5.

Recent results — preliminary, needs further review

  • Recombinant EphB4-HSA Fusion Protein was evaluated in a Phase 2 study 1.
  • Pomalidomide was assessed in a Phase 2 trial, where the incidence of Grade 3 or higher toxicities was reported at 57.7% and 38.5% respectively 2.
  • SSW Works showed varying results for percentage change from baseline employee sunburn prevalence at 1 year (90%, 91%, 35%, and 23%) 3.
  • Aldesleukin was evaluated in a Phase 2 trial, where clinical response rates (objective tumor regression) varied across groups (27.5%, 27.1%, 19.6%, 37.5%, 0%, and 0%) 6.

For the clinician treating this condition

  • Pembrolizumab is established in clinical literature for skin cancer, though it is associated with a 100% incidence of adverse events in reported cohorts.
  • A topical antibiotic product significantly reduces the risk of surgical site infections compared to standard care.
  • Recent trials are investigating various novel agents including Recombinant EphB4-HSA Fusion Protein and Pomalidomide, though large-scale outcomes for these specific interventions remain pending.

AI synthesis of 8 cited trials, updated Jun 28, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this condition. Check back soon.